This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Fecal Microbiome Transplant

This study is currently recruiting participants.
See Contacts and Locations
Verified January 2017 by Children's Hospital of Philadelphia
Sponsor:
Information provided by (Responsible Party):
Children's Hospital of Philadelphia
ClinicalTrials.gov Identifier:
NCT02636517
First received: December 16, 2015
Last updated: January 9, 2017
Last verified: January 2017
  Purpose

Fecal Microbiota Transplant (FMT) in pediatric patients with recurrent C. Difficile with or without Inflammatory Bowel Disease (IBD)

The aims of this study are to determine the safety and efficacy of FMT treatment in pediatric patients with recurrent or moderate to severe C. Difficile without (through an observational study) and with (through a clinical trial) Inflammatory Bowel Disease and to determine the effect of FMT on the gut microbiota through the use of 454 pyrosequencing before and after transplantation in these patients.


Condition Intervention
Clostridium Difficile Inflammatory Bowel Disease Crohn's Disease Ulcerative Colitis Biological: Fecal Microbiota Transplant

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Fecal Microbiome Transplant in Pediatric C. Difficile

Resource links provided by NLM:


Further study details as provided by Children's Hospital of Philadelphia:

Primary Outcome Measures:
  • Number of subjects with a recurrence of C. difficile (CDI) [ Time Frame: 7 days ]
    The hypothesis is that FMT will be an effective therapy for patients with IBD and CDI, resulting in resolution of symptoms as compared to historical controls on antibiotic therapy.


Estimated Enrollment: 50
Study Start Date: December 2015
Estimated Study Completion Date: December 2018
Estimated Primary Completion Date: December 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
C. Difficile without IBD
Fecal Microbiota transplant in pediatric patients with recurrent C. Difficile
Biological: Fecal Microbiota Transplant
Fecal Microbiota transplant via colonoscopy, considered both a biologic and a drug
C. Difficile with IBD
Fecal Microbiota transplant in pediatric patients with recurrent C. Difficile with Inflammatory Bowel Disease
Biological: Fecal Microbiota Transplant
Fecal Microbiota transplant via colonoscopy, considered both a biologic and a drug

  Eligibility

Ages Eligible for Study:   3 Years to 21 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Diagnosis of Inflammatory Bowel Disease by colonoscopy, radiographic and clinic measures, as per standard protocol.
  2. Age ≥ 3 years old.
  3. Recurrent C. difficile or Moderate to Severe C. difficile.
  4. Satisfactory completion of the medical interview and physical exam conducted by a study team member
  5. Participants must be between 3 and 21 years of age (inclusive)
  6. Negative serologic testing to document baseline status within one month prior to FMT, to including, but not limited to: HIV 1 & 2, Hepatitis A total, Hepatitis B surface Ag, surface Ab and core Ab, Hepatitis C Ab, rapid plasma reagin (RPR)
  7. Signed informed consent form, and assent (if applicable)

Exclusion Criteria:

  1. Patients <3 years old
  2. Patients with other co-morbid intestinal infectious processes
  3. Patients will be excluded if on immunosuppressive therapy within 2 weeks of FMT. Clinical care will not be adjusted in order to meet criteria of this study.
  4. Patients currently receiving chemotherapy
  5. Recipients with a history of severe (anaphylactic) food allergy
  6. If female, participants of childbearing potential (females aged 11 and older or those who have already begun menstruating) will be required to have a urine pregnancy test on the day of the FMT procedure. Patients who are pregnant will not be enrolled.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02636517

Contacts
Contact: Judith Kelsen, MD 267-426-6822 kelsen@email.chop.edu
Contact: Melissa Kennedy, MD 267-426-1495 kennedym1@email.chop.edu

Locations
United States, Pennsylvania
Children's Hospital of Philadelphia Recruiting
Philadelphia, Pennsylvania, United States, 19104
Contact: Judith Kelsen, MD    267-426-6822    kelsen@email.chop.edu   
Contact: Melissa Kennedy, MD    267-426-1495    kennedym1@email.chop.edu   
Sponsors and Collaborators
Children's Hospital of Philadelphia
Investigators
Principal Investigator: Judith Kelsen, MD Children's Hospital of Philadelphia
  More Information

Responsible Party: Children's Hospital of Philadelphia
ClinicalTrials.gov Identifier: NCT02636517     History of Changes
Other Study ID Numbers: 13-010531
Study First Received: December 16, 2015
Last Updated: January 9, 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by Children's Hospital of Philadelphia:
Fecal Microbiota transplant

Additional relevant MeSH terms:
Crohn Disease
Colitis, Ulcerative
Inflammatory Bowel Diseases
Gastroenteritis
Gastrointestinal Diseases
Digestive System Diseases
Intestinal Diseases
Colitis
Colonic Diseases

ClinicalTrials.gov processed this record on September 21, 2017